Routine clinical monitoring of sirolimus (rapamycin) whole-blood concentrations by HPLC with ultraviolet detection

Clinical Chemistry

Volumn 42, Issue 12, 1996, Pages 1943-1948

  Napoli, Kimberly L ^a   Kahan, Barry D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

clinical trials; cyclosporine; drug monitoring; pharmacokinetics

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ANALYTIC METHOD; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; GRAFT REJECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; QUALITY CONTROL;

EID: 0029829769     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/42.12.1943     Document Type: Article

References (14)

1. Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin Pharmacol Ther 1992;51:465-73.
2. Shaw LM, Bonner HS, Fields L, Lieberman R. The use of concentration measurements of parent drug and metabolites during drug trials. Ther Drug Monit 1993;15:483-7.
3. Sattler M, Guengerich FP, Yun C-H, Christians U, Sewing K-F. Cytochrome P4503A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992;20:753-61.
4. Sewing K-F, Streit F, Schiebel HM, Napoli K, Kahan BD, Christians U. Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood and urine of kidney graft recipients using HPLC/electro-spray-mass spectrometry (LC/ES/MS) [Abstract]. Ther Drug Monit 1995;17:431.
5. Streit F, Christians U, Schiebel H-M, Napoli KL, Ernst L, Linck A, et al. Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Clin Chem 1996;42:1417-25.
6. Yatscoff RW, Faraci C, Bolingbroke P. Measurement of rapamycin in whole blood using reverse-phase high-performance liquid chromatography. Ther Drug Monit 1992;14:138-41.
7. Fryer J, Yatscoff RW, Pascoe EA, Thliveris J. The relationship of blood concentrations of rapamycin and cyclosporine to suppression of allograft rejection in a rabbit heterotopic heart transplant model. Transplantation 1993;55:340-5.
8. Napoli KL, Kahan BD. Sample clean-up and high-performance liquid chromatographic techniques for measurement of whole blood rapamycin concentrations. J Chromatogr 1994;654:111-20.
9. Wang CP, Scatina J, Sisenwine SF. A high performance liquid chromatographic method for the determination of rapamycin (sirolimus) in rat serum, plasma, and blood and in monkey serum. J Liq Chromatogr 1995;18:1801-8.
10. Svensson JO, Brattström C, Säwe J. Determination of rapamycin in whole blood by HPLC [Abstract]. Ther Drug Monit 1995;17:401.
11. Yatscoff R, LeGatt D, Keenan R, Chackowsky P. Blood distribution of rapamycin. Transplantation 1993;56:1202-6.
12. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993;54:205-18.
13. Yatscoff RW, Boeckx R, Holt DW, Kahan BD, LeGatt DF, Sehgal S, et al. Consensus guidelines for therapeutic drug monitoring of rapamycin: report of the consensus panel. Ther Drug Monit 1995;17:676-80.
14. Deming WE. Statistical adjustments of data. New York: Wiley and Sons, 1943:184.